Toxicogenetics: Applications and opportunities

Toxicological Sciences

Volumn 75, Issue 1, 2003, Pages 1-6

  Orphanides, George ^a   Kimber, Ian ^a  

^a JEALOTT S HILL INTERNATIONAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALLERGEN; CARBAMAZEPINE; DIAZEPAM; ENVIRONMENTAL CHEMICAL; OMEPRAZOLE; RNA DIRECTED DNA POLYMERASE INHIBITOR; WARFARIN;

DRUG RESPONSE; FEVER; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; HUMAN GENOME; RASH; RESPIRATORY TRACT DISEASE; REVIEW; TOXICOLOGY;

GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HUMANS; POLYMORPHISM, GENETIC; TOXICOGENETICS; VARIATION (GENETICS);

EID: 0042383038     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/kfg101     Document Type: Review

References (38)

1. Afshari, C. A., Nuwaysir, E. F., and Barrett, J. C., (1999). Application of complementary DNA microarray technology to carcinogen identification, toxicology, and drug-safety evaluation. Cancer Res. 59, 4759-4760.
2. Aithal, G., Day, C., Kesteven, P., and Daly, A. (1999). Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719.
3. Alberts, B., Johnson, A., Lewis, J., Raff, R., Roberts, K., and Walker, P. (2002). Molecular Biology of the Cell, 4th ed. Garland Publishing, New York.
4. Birren, B., Green, E. D., Klapholz, S., Myers, R. M., and Roskams, J. (1998). Genome analysis: A laboratory manual: Mapping genome (Genome Analysis Series, vol. 4). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
5. Danielson, P. B. (2002). The cytochrome p450 superfamily: Biochemistry, evolution, and drug metabolism in humans. Curr. Drug Metab. 3, 561-597.
6. Farr, S., and Dunn, R. T., II (1999). Concise review: Gene expression applied to toxicology. Toxicol. Sci. 50, 1-9.
7. Gant, T. W. (2002). Classifying toxicity and pathology by gene-expression profile - taking a lead from studies in neoplasia. Trends Pharm. Sci. 23, 388-393.
8. Gawroriska-Szklarz, B., Pawlik, A., Czaja-Bulsa, G., Gornik, W., Luszawska-Kutrzeba, T., and Wrzesniewska, J. (2001). Genotype of N-acetyltransferase 2 (NAT2) polymorphism in children with immunoglobulin E-mediated food allergy. Pharmacogenet. Genomics 69, 372-378.
9. Habener, J. F., and Williams, G. H. (2002). Metabolic Basis of Common Inherited Diseases, 1st ed. W.B Saunders.
10. Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker, K. L., Spreen, W., Lai, E., Davies, K., Handley, A., Dow, D. J., et al. (2002). Genetic variations in the HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122.
11. Iida, A., Saito, S., Sekine, A., Harigae, S., Osawa, S., Mishima, C., Kondo, K., Kitamura, Y., and Nakamura, Y. (2001). Catalog of 46 single nucleotide polymorphisms (SNPs) in the microsomal glutathione S-transferase 1 (MGST1) gene. J. Hum. Genet. 46, 590-594.
12. Ingelman-Sundberg, M., Oscarson, M., and McLellan, R. A. (1999). Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends Pharmacol. Sci. 20, 342-349.
13. Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjoqvist, F., and Ingelman-Sundberg, M. (1993). Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. U.S.A. 90, 11825-11829.
14. Karjalainen, J., Hulkkonen, J., Nieminen, M. M., Huhtala, H., Aromaa, A., Klaukka, T., and Hurme, M. (2003). Interleukin-10 gene-promoter region polymorphism is associated with eosinophil count and circulating immunoglobulin E in adult asthma. Clin. Exp. Allergy 33, 78-83.
15. King, R. A., Rotter, J. I., and Motulsky, A. G. (2002). The Genetic Basis of Common Diseases, 2nd ed. (Oxford monographs on medical genetics, 44). Oxford University Press, Oxford, UK.
16. Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391.
17. Lai, E., Riley, J., Purvis, I., and Roses, A. (1998). A 4-Mb high-density, single nucleotide polymorphism-based map around human APOE. Genomics 54, 31-38.
18. Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A. M., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002). Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727-732.
19. Marez, D., Legrand, M., Sabbagh, N., Guidice, J. M., Spire, C., Lafitte, J. J., Meyer, U. A., and Broly, F. (1997). Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7, 193-202.
20. Nebert, D. W. (1999). Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist? Clin. Genet. 56, 247-258.
21. Nebert, D. W., and Russell, D. W. (2002). Clinical importance of the cytochromes P450. Lancet 360, 1155-1162.
22. Nelson, D. R. (1999). Cytochrome P450 and the individuality of species. Arch. Biochem. Biophys. 369, 1-10.
23. Nuwasyr, E. F., Bittner, M., Trent, J., Barrett, J. C., and Afshari, C. A. (1999). Microarrays and toxicology: The advent of toxicogenomics. Mol. Carcinog. 24, 153-159.
24. Orphanides, G., Pennie, W. D., Moffat, G. J., and Kimber, I. (2001). Toxicogenomics: Theoretical and practical considerations. Comm. Tax. 7, 333-346.
25. Park, B. K., and Pirmohamed, M. (2001). Toxicogenetics in drug development. Toxicol. Lett. 120, 281-291.
26. Pennie, W. D., Tugwood, J. D., Oliver, G. J. A., and Kimber, I. (2000). The principles and practice of toxicogenomics: Applications and opportunities. Toxicol. Sci. 54, 277-283.
27. Pirmohamed, M., and Park, B. K. (1999). The adverse effects of drugs. Hosp. Med. 60, 348-352.
28. Rioux, J. D., Daly, M. J., Silverberg, M. S., Lindblad, K., Steinhart, H., Cohen, Z., Delmonte, T., Kocher, K., Miller, K., Guschwan, S., et al. (2001). Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat. Genet. 29, 223-228.
29. Roses, A. D. (1996). Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 47, 387-400.
30. Roses, A. D. (2000). Pharmacogenetics and the practice of medicine. Nature 405, 857-865.
31. Roses, A. D. (2002). Genome-based pharmacogenetics and the pharmaceutical industry. Nat. Rev. Drug Discov. 1, 541-549.
32. Rushmore, T. H., and Kong, A. N. (2002). Pharmacogenomics, regulation, and signaling pathways of phases I and II drug metabolizing enzymes. Curr. Drug Metab. 3, 481-490.
33. Sachidanandam, R., Weissman, D., Schmidt, S. C., Kakol, J. M., Stein, L. D., Marth, G., Sherry, S., Mullikin, J. C., Mortimore, B. J., Willey, D. L., et al. (2001). A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409, 928-933.
34. Strange, R. C., Spiteri, M. A., Ramachandran, S., and Fryer, A. A. (2001). Glutathione S-transferase family of enzymes. Mutat. Res. 482, 21-26.
35. Taube, J., Halsall, D., and Baglin, T. (2000). Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96, 1816-1819.
36. Ulrich, R., and Friend, S. H. (2002). Toxicogenomics and drug discovery: Will new technologies help us produce better drugs? Nat. Rev. Drug Disc. 1, 84-88
37. Wolf, C. R., Smith, G., and Smith, R. L. (2000). Science, medicine, and the future: Pharmacogenetics. Br. Med. J. 320, 987-990.
38. Yucesoy, B., Vallyathan, V., Landsittel, D. P., Sharp, D. S., Weston, A., Burleson, G. R., Simeonova, P., McKinstry, M., and Luster, M. I. (2001). Association of tumor necrosis factor α and interleukin-1 gene polymorphisms with silicosis. Toxicol. App.